Phylogica enters first commercial deal with Opsona to develop drugs for inflammatory diseases

By E. Janene Geiss

Philadelphia, March 16 - Phylogica said Thursday that it has entered into its first commercial partnership agreement with international biotechnology company Opsona Therapeutics to develop a new class of Phylomer drugs targeting inflammatory diseases.

Opsona is a leader in immunology, having recently completed a deal with multinational drug company Wyeth Pharmaceuticals for the discovery, development and commercialization of compounds to treat inflammatory diseases, officials said in a company news release.

Following completion of the agreement, both companies said they intend for relevant Phylomer compounds to be out-licensed and developed by Opsona with Phylogica to share in the revenue stream.

Phylogica said it could expect to receive customary payments for a deal of this stage, including royalties on sales.

"Phylogica continues to identify collaborations that advance our Phylomer technology, expand pharmaceutical applications and generate revenue," Stewart Washer, chief executive officer of Phylogica, said in the release.

The collaboration is in the area of Toll-Like Receptors and T-regulatory cells, officials said. These targets have been implicated to play a key role in a number of inflammatory diseases including sepsis, asthma, autoimmune diseases and atopic dermatitis.

The new deal with Opsona is the latest is a series of strategic collaborations between Phylogica and leading groups to develop Phylomer drugs for inflammatory diseases such as stroke, rheumatoid arthritis, diabetes and burn injuries.

Opsona is a Dublin, Ireland, drug discovery and development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases.

Phylogica is a Perth, Australia, drug discovery company using its proprietary Phylomer technology to develop a new drug for stroke and other anti-inflammatory diseases including rheumatoid arthritis and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.